Daniel Yokell
Vice President - Theranostic NeuroOncology Telix Pharmaceuticals
Seminars
Thursday 19th February 2026
Roundtable – Breaking Down Barriers in the Traditional Dogma of Drug Development for GBM to Overcome Delays in Bringing Combination Therapies to Patients
2:30 pm
- How can the GBM field move beyond traditional IP models to foster collaboration for combination therapies?
- How can the GBM community standardize preclinical models, data, and trial designs to prevent the wasteful duplication of work?
- What changes are needed in trial design and regulatory pathways to overcome the delays in bringing combination therapies to market?
Wednesday 18th February 2026
Reconsidering the Design of Phase II/III Clinical Trials to Ensure Patients Overcome Challenges with Standard Control Arms for More Streamlined Trials
1:00 pm
- Discussing strategies for molecular profiling and imaging biomarkers to successfully stratify patients for clinical trials
- Exploring innovative control arms using AI and predictive measure to address budget constraints and patient recruitment challenges
- Overcoming current standard of care involving toxic agents such as TMZ that might hinder the potential benefits of novel therapeutics
Wednesday 18th February 2026
Driving the Use of Biomarker-Based Enrollment in GBM trials to Accelerate Clinical Success & Improve Patient Outcomes
1:30 pm
- Addressing the lack of analysis of molecular data in current enrolment protocols for GBM trials
- Discussing strategies to incorporate biomarker-based enrolment given the rise of personalized therapies
- Establishing the efficacy of targeted treatments in recurrent GBM to accelerate the delivery of peronalized therapies
Tuesday 17th February 2026
Advancing Imaging Techniques to Tackle Challenges Associated with Pseudo-progression & Pseudo-response in Glioblastoma Patients
8:00 am
- Join this workshop to discuss best practices and future innovations in brain imaging to distinguish between pseudo-responses and real changes more effectively in GBMs
- Exploring strategies to avoid serial brain biopsies GBM drug development to accurately assess dose selection and discover new biomarkers without invasive techniques
- Discussing advanced neuroimaging strategies to address the challenges of high glucose uptake in the brain such as novel PET ligands that target GBM metabolic pathways beyond glucose
- Evaluating the RANO assessment in modern GBM trials, focussing on how pseudo-progression and pseudo-responses can confound a drug’s true efficacy
- Exploring novel and complementary assessment methods, such as volumetric analysis, advanced imaging biomarkers, and the integration of iRANO criteria for GBM immunotherapies, that can provide a more accurate and reproducible picture of tumor response
- Addressing the practical challenges of standardizing new methodologies across different clinical sites and the regulatory considerations for their use as primary or secondary endpoints
